Research programme: slow off-rate modified aptamers - SomaLogic/OtsukaAlternative Names: SL1026; SOMAmer®
Latest Information Update: 12 Dec 2015
At a glance
- Originator SomaLogic
- Developer Otsuka Pharmaceutical; SomaLogic
- Class Nucleotide aptamers; Peptide aptamers
- Mechanism of Action Interleukin 6 inhibitors; Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rheumatoid arthritis